Trials / NCT05805007
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
Recruiting now Early Phase 1 Gene editing, Gene therapy
- Sponsor
- Peking University Third Hospital
- Treatment
- ZVS203e
- Gene
- RHO
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 9 participants
- Started
- 2023-09-12
- Main results expected
- 2026-12
- Results posted
- Not yet
- Record last updated
- 2026-10-15
What the study is testing
The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of ZVS203e administered via subretinal injection in participants with RP caused by RHO site-specific gene mutation (RHO-RP). This is a single-arm, open-label, single ascending dose study.
Where it runs
China (1)
- Peking University Third Hospital, Beijing, Beijing Municipality (recruiting now)